Get the Stockscreener App
91.18
0.53%
-0.4816
Mirum Pharmaceuticals Inc stock is traded at $91.18, with a volume of 46,429.
It is down -0.53% in the last 24 hours and down -13.57% over the past month.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
See More
Previous Close:
$91.66
Open:
$90.75
24h Volume:
46,429
Relative Volume:
0.06
Market Cap:
$5.50B
Revenue:
$521.31M
Net Income/Loss:
$-23.36M
P/E Ratio:
-190.71
EPS:
-0.4781
Net Cash Flow:
$54.87M
1W Performance:
+1.55%
1M Performance:
-13.57%
6M Performance:
+22.58%
1Y Performance:
+93.45%
1-Day Range:
$90.00
$92.00
1-Week Range:
$89.74
$96.65
52-Week Range:
$36.88
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
91.17 | 5.53B | 521.31M | -23.36M | 54.87M | -0.4781 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.77 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.61 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
685.90 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.47 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.62 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
RBC Capital initiates coverage of Mirum Pharmaceuticals (MIRM) with outperform recommendation - MSN
Why Mirum Pharmaceuticals Stock Is Sinking Today - TipRanks
Penn Capital Management Company LLC Sells 34,265 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 40,985 Shares - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells 16,515 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 4,732 Shares - MarketBeat
Mirum Pharma’s chief medical officer Quan sells $670k in stock - Investing.com Canada
Mirum Pharmaceuticals Executives Sell Shares - TradingView
Mirum (NASDAQ: MIRM) CFO exercises performance RSUs, sells shares to cover tax withholding - Stock Titan
Mirum (MIRM) CMO exercises performance RSUs, sells 7,287 shares for tax - Stock Titan
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Mirum (MIRM) president sells 16,515 shares, exercises 30,220 RSUs - Stock Titan
Mirum (NASDAQ: MIRM) SVP exercises PRSUs, sells 4,732 shares for taxes - Stock Titan
Mirum (MIRM) CEO sells shares to cover tax from RSU vesting - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) files to sell 7,287 vested RSU shares - Stock Titan
Joanne Quan to Sell 7,287 Mirum Shares (NASDAQ: MIRM) via Morgan Stanley - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) insider files to sell 16,515 shares - Stock Titan
Mirum Pharmaceuticals (MIRM) files Form 144: proposed resale of vested RSUs - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) insider sells vested RSUs totaling multiple transactions - Stock Titan
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli - The Globe and Mail
Mirum completes enrollment & screening in liver disease studies - MSN
Aquatic Capital Management LLC Boosts Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum completes enrollment in cholestatic pruritus trial By Investing.com - Investing.com India
Trading Recap: Is Mirum Pharmaceuticals Inc a turnaround story2026 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Mirum Pharmaceuticals releases latest announcement details - Traders Union
Saira Ramasastry to sell 2,000 shares via option exercise (NASDAQ: MIRM) - Stock Titan
Mirum completes enrollment in cholestatic pruritus trial - Investing.com
Rare liver disease trial of Mirum itch drug finishes signup - Stock Titan
Algert Global LLC Buys 31,250 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Eventide Asset Management LLC Sells 114,922 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Stock Holdings Reduced by Boone Capital Management LLC - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall - Sahm
Aug Patterns: Can Mirum Pharmaceuticals Inc benefit from deglobalization2026 Catalysts & Weekly Breakout Watchlists - baoquankhu1.vn
Does Advancing Brelovitug Into Late-Stage HDV Trials Change The Bull Case For Mirum Pharmaceuticals (MIRM)? - simplywall.st
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Mirum Pharmaceuticals (MIRM) president and COO exercises options, lifts stake - Stock Titan
Mirum Pharmaceuticals at Leerink Conference: Strategic Growth Plans By Investing.com - Investing.com Canada
Mirum Pharmaceuticals at Citizens Life Sciences: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (MIRM) and Scalable Risk - Stock Traders Daily
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Teachers Retirement System of The State of Kentucky Invests $1.08 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) earnings expected to grow: What to know ahead of Q4 release - MSN
Mirum’s Brelovitug Phase 3 Milestones Reframe Rare Disease Growth Story - simplywall.st
Mirum Finishes Participant Enrollment and Screening for Liver Disease Research - Bitget
Mirum Completes Enrollment & Screening in Liver Disease Studies - Barchart
TD Asset Management Inc Buys Shares of 15,400 Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):